businesspress24.com - 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum Announces Presenting Compani
 

2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum Announces Presenting Companies and Panelists

ID: 1156950

Agenda to Include Interactive Panels and Case Studies Featuring Key Opinion Leaders

(firmenpresse) - WASHINGTON, DC -- (Marketwire) -- 10/03/12 -- The 2012 Stem Cell Meeting on the Mesa today announced further details of the agenda for its second annual Investor and Partnering Forum. The conference will include 35 corporate presentations, a distinguished plenary session and a series of panel discussions featuring several of the field's key opinion leaders.

The event will take place October 29-30, 2012 at the Sanford Consortium for Regenerative Medicine Building, La Jolla, California. The Stem Cell Meeting on the Mesa's Scientific Symposium will immediately follow the Investor & Partnering Forum on October 31, 2012 at the Salk Institute. Combined, these meetings will attract over 800 attendees from around the globe, highlighting the promise and progress of this rapidly evolving, interdisciplinary field.

Advanced Cell Technology, AlloSource, Athersys, Capricor, Cedars-Sinai Medical Center, Cellular Dynamics International, Cytomedix, Cytori, DiscGenics, Eqalix, Healthpoint Biotherapeutics, Juventas Therapeutics, MaxCyte, Medistem, Nanofiber Solutions, NeoStem, New York Stem Cell Foundation, Organovo, Owl Biomedical, Q Therapeutics, Regen BioPharma, Regenerative Patch Technologies, Rhinocyte, Sangamo, Sistemic, Stanford University School of Medicine, StemBioSys, StemCells, Inc., TAP Biosystems, TheraBiologics, TiGenix, UC Davis Institute for Regenerative Cures, ViaCyte

The Investor and Partnering Forum will also include panel discussions and case studies focused on finance, commercialization, regulatory and reimbursement of regenerative medicine technologies with speakers from leading companies, government agencies and organizations. Selected panelists include:

Kimberly Benton, Deputy Director, CBER, FDA

Greg Lucier, Chairman & CEO, Life Technologies

Geoff MacKay, President & CEO, Organogenesis

Paul Simmons, Executive Vice President, Corporate Research & Product Development, Mesoblast

Matthias Steger, Global Head, Research & Technology Partnering, Roche





Dean Tozer, Senior VP, Corporate Development, Shire Regenerative Medicine

J. Craig Venter, Founder, Chairman & President, J. Craig Venter Institute

The Investor and Partnering Forum is being organized by the Alliance for Regenerative Medicine (ARM), CIRM and the Sanford Consortium to facilitate translational research, promote engagement between the scientific and business communities and provide opportunities for business, academic research and investor participants to connect in one-on-one strategic partnering meetings.

To learn more or to register for the 2012 Stem Cell Meeting on the Mesa Symposium and Investor & Partnering Forum, please visit . Registration is complimentary for credentialed members of the media.

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit .



Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Charles Hensley, Ph.D., and Itonis Pharmaceuticals Announce Anti-HIV Compound Targeting the Viral Entry Step
Theratechnologies to Announce Financial Results for Third Quarter of 2012
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 03.10.2012 - 07:49 Uhr
Sprache: Deutsch
News-ID 1156950
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

WASHINGTON, DC


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 230 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum Announces Presenting Companies and Panelists
"
steht unter der journalistisch-redaktionellen Verantwortung von

The Alliance for Regenerative Medicine (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von The Alliance for Regenerative Medicine



 

Who is online

All members: 10 567
Register today: 2
Register yesterday: 0
Members online: 0
Guests online: 82


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.